Figures
Abstract
Cross-sector partnerships are vital for maintaining resilient health systems; however, few studies have sought to empirically assess the barriers and enablers of effective and responsible partnerships during public health emergencies. Through a qualitative, multiple case study, we analyzed 210 documents and conducted 26 interviews with stakeholders in three real-world partnerships between Canadian health organizations and private technology startups during the COVID-19 pandemic. The three partnerships involved: 1) deploying a virtual care platform to care for COVID-19 patients at one hospital, 2) deploying a secure messaging platform for physicians at another hospital, and 3) using data science to support a public health organization. Our results demonstrate that a public health emergency created time and resource pressures throughout a partnership. Given these constraints, early and sustained alignment on the core problem was critical for success. Moreover, governance processes designed for normal operations, such as procurement, were triaged and streamlined. Social learning, or the process of learning from observing others, offset some time and resource pressures. Social learning took many forms ranging from informal conversations between individuals at peer organisations (e.g., hospital chief information officers) to standing meetings at the local university’s city-wide COVID-19 response table. We also found that startups’ flexibility and understanding of the local context enabled them to play a highly valuable role in emergency response. However, pandemic fueled “hypergrowth” created risks for startups, such as introducing opportunities for deviation away from their core value proposition. Finally, we found each partnership navigated intense workloads, burnout, and personnel turnover through the pandemic. Strong partnerships required healthy, motivated teams. Visibility into and engagement in partnership governance, belief in partnership impact, and strong emotional intelligence in managers promoted team well-being. Taken together, these findings can help to bridge the theory-to-practice gap and guide effective cross-sector partnerships during public health emergencies.
Author summary
Digital technologies have played a unprecedented role in emergency response during the COVID-19 pandemic. Partnerships between private sector technology companies and health institutions, such as hospitals and public health organizations, are often necessary to develop and deploy digital technologies. Here, we sought to understand the barriers and enablers to forming effective and responsible cross-sector partnerships during a public health emergency—with a focus on the role of startups. The firms we studied triaged and streamlined various governance processes (e.g., stakeholder assessment, contracting, procurement) in response to COVID-19’s time and resource pressures. Informants articulated the paramount importance of achieving early and sustained alignment on the core problem to be solved and how governance structures (e.g., connections between team members at different levels of seniority) facilitated this alignment. Flexibility and deep knowledge of the local operating context provided startups with an immense competitive advantage. Key areas for improving partnerships include: knowledge translation to promote the uptake of governance frameworks among decision-makers, accelerating public sector procurement processes that are too long and complex to be financially viable for startups, and developing pragmatic, public engagement strategies to build trust and promote social acceptability.
Citation: Harish V, Samson TG, Diemert L, Tuite A, Mamdani M, Khan K, et al. (2022) Governing partnerships with technology companies as part of the COVID-19 response in Canada: A qualitative case study. PLOS Digit Health 1(12): e0000164. https://doi.org/10.1371/journal.pdig.0000164
Editor: J. Mark Ansermino, University of British Columbia, CANADA
Received: June 22, 2022; Accepted: November 14, 2022; Published: December 14, 2022
Copyright: © 2022 Harish et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: This study uses qualitative data and due to the nature and identifiability of the organizations and participants involved in this study, the data (documents and interview transcripts) underlying this work cannot be shared as per our consent process. Anonymized search terms are provided in the Supplementary Material.
Funding: V.H. was supported through an Ontario Graduate Scholarship, Canadian Institutes of Health Research Banting and Best Master’s and Doctoral Awards, Vector Institute Postgraduate Affiliate Award, University of Toronto Centre for Ethics Fellowship, and Schwartz Reisman Institute for Technology and Society Graduate Fellowship. T.S. was supported through the Temerty Centre for Artificial Intelligence Research and Education in Medicine Summer Studentship. M.M. was supported through the Odette Chair in Advanced Analytics at Unity Health Toronto. K.K. was supported through a Temerty Health Nexus Chair in Health Innovation and Technology at the University of Toronto. L.R. was supported through a Canada Research Chair in Population Health Analytics and Stephen Family Research Chair in Community Health at Trillium Health Partners.
Competing interests: K.K. is the founder of BlueDot, a B corporation that develops digital solutions for public health. The other authors have no conflicts to disclose.
Introduction
COVID-19 has upended health systems, economies, and daily life around the globe. Given the immense burden the pandemic has placed on health systems, there has been a resurgence in the discussion of health systems resilience among practitioners and researchers [1]. Health systems resilience reflects preparedness for an emergency as well as the capacity in the system to respond effectively to emergencies while maintaining core functions [2]. Health emergencies such as pandemics have broad impacts across society and thus a key principle that characterizes resilient health systems is the capacity to coordinate actions across the public, private, and non-profit sectors [2].
Past public health crises such as pandemic H1N1 and the 2014–2016 Ebola epidemic have generated calls to action around fostering effective cross-sector partnerships [3–5]. The COVID-19 crisis is unique due to the previously unprecedented role of digital technologies, and thus private technology companies, in pandemic response [6]. From digital contact tracing (DCT), to ledgers organizing vaccine administration, to machine learning-based risk prediction models of severe clinical outcomes—medical and public health organizations have sought to leverage digital technologies to support pandemic response [7–9]. However, health organizations traditionally do not have the skillset to develop and deploy such technologies in-house, especially in the context of a rapidly evolving public health emergency [10]. Therefore, partnerships with private technology companies, both large and small, have become increasingly common. The governance arrangements underlying these collaborations are essential for social license as well as the likelihood and success of technology development and uptake [11].
The concept of social license, or a social license to operate, is a community’s perceptions of the acceptability of a company and its local operations [12]. It refers to the informal permissions granted to institutions such as governments or corporations to carry out a particular set of activities [11]. Building social license encapsulates legitimacy, credibility, and trust between a given organization, stakeholders within and outside of said organization, and the general public [12,13]. As such, civil society may have demands or expectations that surpass those imposed by legal regulations [14]. One area particularly relevant to partnerships between health organizations and private-technology companies is data privacy and security. Personal information in Canada is protected by different regulations depending on the handling entity: the Privacy Act for the federal government [15], the Personal Information Protection and Electronic Documents Act (PIPEDA) for private sector organizations [16], and provincial health legislation for hospitals and other similar institutions that serve as custodians of personal health information. In Ontario, Canada’s largest province, the data legislation for hospitals, long-term care homes, and pharmacies is titled “the Personal Health Information Act” (PHIPA) [17]. Even if a partnership adheres to these regulations, it is possible that it may not obtain social license due to a wide range of governance factors such as a lack of transparency, lack of public engagement, and data sharing beyond what is perceived necessary [11].
While there is growing discourse around the ethics of collaborations between technology companies and health organizations [18], there is a dearth of research investigating this type of collaboration in-depth as it is deployed during a public emergency. During the COVID-19 pandemic, much attention has been placed on DCT, but DCT is only one specific type of technology deployment within a broader taxonomy of digital health tools [19–21]. Finally, much of the literature in this area focuses on major multinational companies, such as Google DeepMind and IBM [22,23]. While these “Big Tech” companies have formed over thirty partnerships with hospitals and health systems globally, they are not the only players in this space [24]. Funding for digital health startups has been growing year-over-year, with US startups raising almost $30B USD and European startups raising $8.1B USD in 2021 [25,26]. Throughout the pandemic, health organizations and startups around the world have formed partnerships across clinical, operational, and population health domains [27–29]. Compared to Big Tech, startups face the “liability of newness” and “liability of smallness” [30]. Since startups are often small and resource-scarce, they are can be vulnerable to financial pressures, human resource shifts, and external shocks [31]. They may also lack established business models and market legitimacy [30–32]. Forming partnerships is vital to the long-term survival and sustainability of startups [33,34]. From the perspective of health systems partners, the fundamental characteristics of “smallness” and “newness” can also make startups exceedingly valuable as partners. Research from the 2008–2009 financial crisis has found that small firms in the UK and New Zealand demonstrated high levels of adaptability and flexibility [35]. Given their size, local startups may be more accessible to health organizations and logistically easier to partner with. Both smallness and newness also require decision-makers in startups to attend closely to their customers and local market context [36]. Accessibility and understanding of local context can also be magnified by mutual engagement within the local innovation ecosystem [37]. Although partnerships with startups often do not create as much public attention, and perhaps criticism or outrage, as partnerships with Big Tech companies, stakeholders cannot assume partnernships with startups will automatically have social license [38–40]. Ultimately, how best to govern these partnerships in a manner that promotes social license remains an open question that warrants detailed study [41].
Using a qualitative, multiple case study design, we sought to study the governance arrangements between Canadian health organizations and private technology startups during the COVID-19 pandemic. Our objective was to systematically apply a framework of adaptive governance in healthcare to describe and analyze the barriers and enablers of deploying digital technologies as part of the pandemic response. The results of this work are vital to help bridge the theory-to-practice gap and to guide effective and responsible cross-sector partnerships during public health emergencies [42].
Methods
This qualitative study was conducted through use of a multiple case study design [43]. Using a case study design allows researchers to illuminate why a decision–or set of decisions–were taken, how they were implemented, and with what results. When describing case-study research in his popular methodological manual, Robert K. Yin puts forth that a case study “relies on multiple sources of evidence, with data needing to converge in a triangulating fashion” [43]. Examples of common evidence sources researchers select to conduct in-depth study of a phenomenon in its real-world context include: documentation, archival records, interviews, direct observations, participant-observation, and physical artifacts [43]. We selected the complementary methods of a document review as well as interviews with key informants. The purpose of the document review was to provide context into the need for study partnerships, provide a starting point for identifying potential key informants, and gain an understanding into key events and outcomes of the partnerships. Key informant interviews were conducted to explore a range of topics from the drawn upon theoretical frameworks (i.e., Vayena and Blasimme’s framework of systemic oversight, Gasser’s navigation aid for the ethical use of digital public health tools) that we believed would not likely be captured in documents. Key informant interviews can elucidate why and how certain decisions were made—that is provide critical perspectives into partnership governance. Interviews also allow for researchers to challenge their participants by probing on what they thought could have gone differently or be improved upon. Ultimately, we believed that document review and the key informant interviews would provide us with complementary and synergistic findings and contribute to a robust case study. We explain the methodological basis for how we conducted both below.
Our cases were sampled from three separate public/private collaborations to deploy digital technologies as part of the COVID-19 response. These collaborations were broken down into three categories of technologies as outlined by Shaw et al. (2019): clinical, operational, and epidemiological [44]. While there are other taxonomies that have been applied to digital technologies in the context of the pandemic [20,21], these taxonomies and their subcategories are not mutually exclusive. Each of the technology companies were startups.
Technology company A and health organization B partnered to deploy a virtual care platform for staff at long-term care homes to consult physicians regarding the status of COVID-19 patients without having to send them to an emergency room. This virtual care platform also facilitated COVID-19 testing for patients within health organization’s catchment area. Shaw et al. (2019) defined “clinical applications” as those pertaining to the tasks of assessing, evaluating, and intervening on health issues [44]. Since these applications are directly related to the task of patient assessment and evaluation, we selected this partnership as our “clinical” collaboration.
Technology company C and health organization D partnered to deploy a secure messaging platform for physicians. Physicians used this platform, in part, to coordinate the care of COVID-19 patients. Physicians would receive notifications on this platform when tests returned positive with SARS-CoV-2, use the platform to request consults with other services, and serve as a digital pager when on call. As per the definition proposed by Shaw et al. (2019), these tasks are ancillary to, but essential for delivering clinical services [44]. Therefore, we selected this partnership as our “operational” collaboration.
Technology company E partnered with health organization F to provide data science consulting regarding the management and spread of COVID-19 at the population-level. Part of this consulting involved leveraging novel, digital data streams. As such, we selected this partnership as our “epidemiological” collaboration of study in line with the definition proposed by Shaw et al. (2019) [44].
The methods were performed in accordance with relevant guidelines and regulations and approved by the University of Toronto’s Health Sciences Research Ethics Board (REB #26448).
Theoretical framework
Since we are studying the governance of collaborations between Canadian public health/health care organizations and private technology companies, we have drawn from a governance framework to inform the methodologies and analysis of our study. Specifically, we used Vayena and Blassime’s framework of systemic oversight [45–47].
Systemic oversight draws upon the extensive literature on adaptive governance, originally developed for application in the environmental sciences. Adaptive governance is a means of coordinating resource management within uncertainty-laden and rapidly changing socio-ecological systems [48,49]. Vayena and Blassime argue that health data, due to its sources, capabilities, and stakeholders, can be characterized as an “ecosystem”, presenting significant implications for its management [45]. The framework is aimed at promoting responsible innovation across biomedical research, patient care, and public health with three aims: 1) to draw attention to ethically controversial areas to address risks, 2) to direct innovation towards outcomes beneficial for society, and 3) to promote public trust and accountability [46]. In keeping with these objectives, systemic oversight: 1) leverages adaptive and flexible mechanisms to cope with uncertainty, 2) is both inclusive and reflexive to engage a wide range of stakeholders and consider how they may be impacted by a given solution, and 3) monitors for and is responsive to emerging risks and harms [45–47].
There are numerous conceptual strengths of this framework for our study. First, it recognizes the ecosystemic and highly interconnected nature of both the digital technologies and the institutions involved in COVID-19 response. Second, it is appropriate for understanding how organizations respond to the COVID-19 pandemic, which is inherently a situation in which actors must act under tremendous uncertainty, time pressures, and constant change (e.g., in the epidemiological and clinical dynamics of the disease, spillover impacts to other aspects of society such as supply chains, etc.). Adaptive governance has been used in similar areas such as managing and mitigating risk due to natural disasters [50]. Third, adaptive governance also aptly relates to the notion of resiliency as both draw from the environmental sciences [48]. Finally, the use of this framework lends itself towards a hypothesis that is grounded in what has been seen in adjacent literature: when the structure of an ecosystem is challenged by crisis, then the mechanisms of governance that were designed optimally to support the ecosystem are at the heart of the crisis and must adapt in ways for which they were not designed.
We opted to employ Blasimme and Vayena’s framework of systemic oversight over other frameworks such as Char’s pipeline [51] or Leslie’s process-based governance framework for AI workflows [52] due to its complementarity and specificity with this study (i.e., we are focused on the governance of a health response to a crisis rather than the ethics surrounding a response). We also focus on the use of digital technologies to meet this response rather than artificial intelligence tools, strictly speaking. We also drew from Gasser et al.’s navigation aid to guide our data collection through semi-structured interviews with key informants [20]. We structured our interviews in accordance with the aid’s conceptual phases of developing and deploying digital technologies: 1) Preparation, 2) Planning, 3) Risk Assessment, 4) Development, 5) Deployment and Evaluation.
Document review
Document analysis included documents that provided details on the structure and nature of the sampled partnerships. Documents were included if they included details of the partnership, leadership perspectives, outcome measures, regulatory landscape, or product features. The search for these documents was done through multiple Google searches and manual searches in sampled organization webpages by following links. This process was done independently by two individuals (VH, TS) while keeping track of search terms (Appendix A in S1 Text). Searching and data abstraction was done by two independent reviewers (VH and TS), with conflicts resolved by discussion. We performed two rounds of document review (summer 2021, winter 2022) to account for new updates regarding the partnerships or organizations involved during the study period.
Key informant interviews
An initial list of key informants was first identified through the document analysis. We then used snowball sampling to identify additional participants at the end of each interview. Participants were recruited by email and were sent a standardized consent form (Appendix B in S1 Text). We sought to recruit participants in the roles of organizational leadership, end-users, and project/product managers, among others. To promote participants speaking freely, we ensured that their identities would be kept anonymous throughout the course of the study and requested that managers not ask if employees participated in the study.
The semi-structured interview guide (Appendix C in S1 Text) served to explore a range of topics from Vayena and Blasimme’s framework of systemic oversight as well as Gasser and colleagues’ navigation aid for the ethical use of digital public health tools [20,45–47].
Using this semi-structured interview guide, we conducted six pilot interviews prior to interviewing key informants to refine the content of the interview guide as well as the length and structure of the interview. We piloted with senior members of the research team and colleagues in similar roles to our key informants (e.g., clinicians, data scientists, etc.), and thus, we did not include the pilot interviews in the analysis.
The consent form was emailed to participants ahead of time, and interviews were conducted over internet-based audio/video chat on Zoom. Interviews were an hour on average and consenting participants had the option to be audio/video recorded. Interviews were then transcribed verbatim using Zoom’s built-in, automated transcription feature and the adequacy of the transcriptions were assessed by VH and TS using recordings. Recordings were then deleted upon ensuring the adequacy of transcription.
Coding and data analysis
To abstract and synthesize data from key informant interviews and publicly available documents, data coding was done iteratively and through the qualitative method of abductive analysis [53]. We selected abductive analysis to move between the data and our a priori theories. The goal of the abductive analysis is to generate novel theoretical insights that reframe empirical findings in contrast to existing theories. The transcribed interviews and document analysis were described using the coding structure-specific in Appendix D in S1 Text. Additional coding domains were developed as needed during the analysis, and the key themes were identified as nodes within the qualitative software package.
As mentioned above, the primary framework used to guide analysis was Blasimme and Vayena’s framework of adaptive governance through systemic oversight because it highlights a range of recommendations that promote responsible big data innovation across biomedical research, patient care, and public health. It also emphasizes the importance of directing attention to ethically controversial areas to address risks while also promoting public trust and accountability. Throughout the analysis, we also allowed thematic content to evolve independently of Blasimme and Vayena’s framework.
All coding was done in duplicate by VH and TS with conflicts resolved by discussion for each document and transcript until consensus was reached. Data collection, organization, and analysis was done using the NVivo qualitative software (version 12, QSR International, Melbourne, Australia). Finally, the data from each case study was gathered and synthesized into a single brief case report to facilitate cross-case synthesis. The results of the cross-case synthesis are presented here. Recruitment and data analysis were done in an iterative process between July 2021 and February 2022.
Sample size adequacy
In keeping with case study methodology, our goal was not to speak to every single stakeholder in each case but rather to understand an issue, process, or phenomenon. We used information power as the criteria for stopping further recruitment in each case once we believed we had a clear and sufficient understanding of the phenomena in each case [54]. Due to our narrow aim (i.e., explore specific partnerships between private technology companies and public sector health organizations), specificity in experiences of our key informants (i.e., had direct involvement with partnerships during COVID-19), use of well-established theory (i.e., Blasimme and Vayena’s theory of adaptive governance), and richness of interview dialogue, we found that five to ten interviews was sufficient to gain an understanding of each case in combination with the documents obtained. We then applied these requirements across our three cases.
Results
We obtained 210 publicly available documents and conducted 26 interviews on our three cases of study between June 2021 and February 2022. A breakdown on the sources and types of documents is presented in Fig 1. Most documents were news articles, marketing materials, and webpages (Fig 1A). Most documents were obtained from company websites (Fig 1B). In what follows, we describe several major themes that emerged over our iterative, abductive analysis of these documents and interviews in relation to our guiding theories. Despite the considerable pressures of the pandemic, we found that each partnership was able to enact key aspects of adaptive governance along the pipeline of solution development to deployment (Table 1). We describe how a health emergency created pressures for our cases and how these pressures were navigated below. We first begin with the time and resource pressures created by the pandemic (theme 1), and then discuss how those pressures demand alignment early in the partnership (theme 2) and the streamlining of governance processes throughout the partnership (theme 3). We then present findings regarding a particularly important governance process, social learning, in detail (theme 4). This is followed by an outline of the specific opportunities and risks for startups during a health emergency (theme 5). Finally, we end with how teams had to navigate all these pressures and remain high-functioning (theme 6).
Pie charts of document type (A) and source (B) from document review, n = 210.
A health emergency ultimately creates tension with time and resources
COVID-19 has been all-consuming for public sector organizations, especially during surges when staff are pulled away from non-pandemic-related activities to maintain core functions.
“… you’re dealing with a pandemic that is pulling every and all possible resources towards it like a big giant star.” (Case 1—Interview -Sales)
The ever-changing nature of the pandemic also created an environment of uncertainty for the partnerships as the health organizations we studied had to respond on very short timelines to developments both in the dynamics of the pandemic itself (e.g., the emergence of new variants such as Delta) or in pandemic-related policies (e.g., changes in testing criteria). These immense demands either catalyzed partnerships with private technology companies to form de novo or for existing partnerships to expand into new areas in reaction to evolving needs, such as keeping track of which patients were COVID-positive in the hospital or who received COVID-19 vaccinations in the community.
“So one of the challenges was that patients who were positive were a needle in the haystack amidst all the negative test… [the solution we built] ensured that everyone was on the same page within an hour of the resulting positive.” (Case 2—Webinar—Chief Medical Information Officer)
These pressures were felt across the different stages of the partnership (Table 2). At the beginning of the partnership, many participants felt that the current procurement regulations for public organizations, including hospitals, were not sufficiently agile in response to the time pressures of the pandemic.
(Gasser et al., Lancet Digital Health 2020).
“So if you’re in a crisis, I just don’t know that you have time for that kind of lengthy [procurement] process because, there are there are pretty significant consequences for a loss of time and, you know, time is non-renewable as a resource you don’t get it back—you can’t rewind the clock… And so that’s the question: do you want to spend that time in that process? I think there needs to be a more agile process.” (Case 3—Interview—Chief Executive Officer)
However, there was a dichotomy to the effect of the pandemic on public-private partnerships: the same time pressures that posed challenges for the partnership also served as a catalyst for them. Participants in the private sector across our three cases felt that the business value of their solutions was made much more apparent during the pandemic. For example, virtual care proliferated in March 2020 because providers needed the means to connect with patients when outpatient clinics were shut down. Moreover, the public sector organizations were able to move much faster during the pandemic to form partnerships partly because leadership had a “burning platform” to act, especially if inaction would also cause harm. Leadership buy-in was an enabler to removing “red tape” that would otherwise stall partnership formation.
“… that pressure of time, it cuts through really debating what’s real and what is like, not a real risk … we’ll sometimes spend months debating like an indemnity clause in a contract about like a potential catastrophic event that’s very unlikely to occur… We were able to move past what would have been months and months of discussion… We were able to make a lot of ground in an emergency situation because we felt that any potential risk was outweighed by the risk of losing lives to COVID-19.” (Case 1—Interview—Vice President #1)
Early and sustained alignment around the problem is core to success
We found that a clear understanding of a central problem was critical to the success of our studied partnerships. Participants noted that successful partnerships were the ones where effort was made by the vendor to deeply understand the client’s pain points during the sales cycle and longitudinally through the partnership.
“So each party I think really has to… figure out where their little Venn diagrams can overlap in the middle to the success of both… in a pandemic that same approach would be even more profoundly important, because speed is not on your side there. You gotta move quicker, faster, and so you better define that common space in the middle, much faster than you would in normal times.” (Case 1—Interview—Incubator Lead)
Once a partnership was underway, participants consistently stressed the importance of continuous transparency around motivations, deliverables, progress, and roadblocks. Transparent communications were viewed as a core enabler of trust that both parties were aligned towards solving the same problem.
“…having that open, honest, and clear communication will allow just, you know for that trust to be built.” (Case 2—Interview—Customer Success)
The success of the partnerships in our case study is also reflected in the establishment of governance structures that support early and continuous alignment through transparency and trust. Logic diagrams demonstrate the multi-level connections between partner organizations, both in healthcare (Fig 2) and in public health (Fig 3). In both cases, the client success role has high centrality within the governance structure and serves as a vital “bridge” between the partners.
“It’s my role within the company to be the voice of the client so I need to understand what the client wants, their needs, their priorities and advocate for them within the company… We are basically at the cross-section of almost every single department, because we are the voice of the client and the client drives the product.” (Case 3—Interview—Customer Success)
Beyond customer success, participants also spoke to the importance of ensuring alignment between different levels of seniority across the partnership and being able to escalate issues appropriately. One participant called this the “zipper:”
“I zipper people in and I make them develop relationships… Those contact points determine success or failure… So as an example [if] you were the director level or PM, I’d have you and your other person report monthly to [tech company A CEO] and myself… And you live and die together…[you need] the zipper, the alignment of interest, the processes to cause reporting, and the honesty to escalate when something’s going wrong [to] deal with it at the right level, you can’t deal with a strategic issue at an operational level.” (Case 1—Interview—Chief of Staff)
The emergency context led to the triage and streamlining of governance processes
Table 3 shows the wide range of tools that were used to govern the partnerships (i.e., governance processes) across our three cases of study. Participants noted that the time and resource pressures of the pandemic led to shifts in certain governance processes, such as identifying goals and allocating tasks, from formal mechanisms (e.g., project charters) to more informal ones (e.g., rapid, huddle-style meetings).
“… clearly identifying what the goals are and articulating what the accountabilities are, my sense is that in an emergency this happened, far more informally than someone literally drafting up a charter or terms of reference … [it would] be like, … “All right, we’re gonna have a huddle, we’re going to spend 30 minutes this way, you’re going to do this, we’re going to do this. All right, let’s go””. (Case 3—Interview—Chief Executive Officer)
While many governance processes were modified to be more efficient, participants also stressed certain processes that were vital and needed to be maintained. For example, stakeholder assessment could not be skipped in its entirety but leveraging the public organization’s ownership and deep understanding of their problem and context allowed for one private organization to identify and prioritize “directly-impacted” groups during an accelerated stakeholder assessment. Moreover, mechanisms around what Blasimme and Vayena term “monitoring” such as maintaining risk registries or keeping track of key performance indicators, could not be dropped altogether because they helped the partnership remain aligned and navigate emerging risks. This is especially true in the context of privacy or security issues.
“I’d say that getting approval and acknowledgment from stakeholders… is a step you just can’t skip… if the stakeholder groups asked you to do something, you should have acknowledgment and awareness at a senior team level that it’s being done.”(Case 1—Interview—Chief Security and Privacy Officer)
An unexpected finding was that participants did not prioritize publicly sharing details of the partnership. Leaders stressed that, especially in the “information overload” context of the pandemic, publicly-directed communications about a given partnership should be meaningful and prioritized around the key needs of stakeholders.
“…especially in the context of COVID for example, [it’s] not always the most appropriate thing to be necessarily like flooding a hospital’s Instagram account to try to market this type of program when like they’re trying to get vaccinations in arms.” (Case 1—Interview—Implementation Manager)
Social learning can offset some emergency pressures
Social learning, defined as learning through observing others [55], was identified by Blasimme and Vayena as a key enabler of governance by systemic oversight and was identified across all three study cases. For the hospitals, social learning occurred both informally (e.g., Chief Information Officers would reach out to each other for advice) and formally (e.g., the local university’s medical school co-ordinated city-wide COVID-19 response tables for hospital leadership that met as often as daily). For some participants, social learning was viewed as a bare minimum level of due diligence needed before embarking on a partnership with a vendor.
“As much as a crisis makes people make rapid decisions—don’t [do that]. Take the time to at least do a, you know, an environmental scan and say like, “hey, what is everybody else doing?”” (Case 1—Interview—Chief Medical Information Officer)
The public health organization we studied also had a small team dedicated to learning from jurisdictions worldwide, but it was less clear how to take these learnings and apply them to their own context compared to the hospitals.
“I think there was an effort to constantly learn from other countries… there’s a group whose only task is to look at other countries, what they’re doing, and how they’re performing as a result of what they’re doing… and that project has been ongoing for at least probably since the summer of 2020.” (Case 3—Interview—Senior Epidemiologist)
For the private technology companies, social learning took the form of press releases, when deemed appropriate, to signal key milestones (e.g., launching new products or services). Conversely, it also involved scanning for other offerings in the market to understand and crystallize their unique value proposition as a company. For one partnership, they noted that social learning was formalized by the nature of their membership in an innovation accelerator, where they delivered and heard presentations about successful and unsuccessful healthtech partnerships from other participants in the program.
Startups have a vital role to play in emergency response, but growth can introduce new challenges
Since the companies studied were startups, we found that they were highly attuned to their local contexts and could often be highly flexible and adaptable to create bespoke solutions for their partners. Several participants from the hospitals contrasted their previous experiences with major electronic medical record (EMR) companies based in the United States, positively reflecting on how their perspectives as end-users were much more valued and regularly informed product updates compared to the EMR companies.
“I think with the big vendors, the other thing is making sure that I’m not getting the short end of the stick where I’m paying a lot but actually not getting service… whereas I think those discussions are easier with a smaller company right because they just have more flexibility” (Case 2—Interview—Chief Information Officer)
All three startups studied scaled dramatically (i.e., doubled, tripled) during the pandemic due to the increased demand for their solutions. While on the one hand, the increased demand and revenue is positive and reinforce their value, aspects of pandemic-fueled “hypergrowth” were also challenging. For example, one dimension of growth was around staffing and building capacity to complete core tasks in response to increased demand, such as responding to customer support tickets or onboarding new users.
“[Virtual care company] experienced a 500% increase in usage and added over 200 healthcare providers to its platform in one month alone.” (Case 1—Marketing brochure)
Such growth often demands changes to governance processes to improve their quality or feasibility.
“So for example… deployments, before it was just [the] wild west, we have this hospital deploying whatever and we think about things off the top of our head… and mistakes happen… With our new process… when we have a hospital deployment, we have every single task created… okay these are things that we have to do, we can delete ones that are not applicable and that makes it much more repeatable and the quality is much better on a wider scale”.—(Case 2—Interview—Chief Executive Officer)
Given the urgent, and oftentimes bespoke, nature of client demands during the pandemic, the companies we studied also had to navigate how to maintain their core value proposition.
“Each client wants a slightly different version of what you’re trying to offer. And so you start to get this just like infinite list of things that you can build against but it only applies to one client at a time, and building like bespoke things at scale is just not possible.” (Case 3—Interview—Product Manager)
There’s no partnership without healthy, motivated teams
The intensity of the pandemic timelines and workloads universally created burnout and a high degree of turnover among teams in both the public and private sectors. Effective interpersonal skills and emotional intelligence, especially empathy, was viewed as an enabler of effective partnerships.
“I’ll typically relate back to you know I get it, I’m a healthcare professional myself, you know, things come up, emergencies come up… I think that that perspective allows me to be there in a more supportive way because I do understand that their environment can be very hectic and can be ever-changing.” (Case 2—Interview—Customer Support)
Participants also spoke to the need for visibility into governance processes. Leaders felt the onus to be active throughout the partnership and diagnose areas of potential misalignment quickly.
“I understood that in that forming stage, it required a tremendous amount of effort and time. And the stakes were high. So the reality is… I’d be talking to that CEO, three times a day. And I’m setting up a steering committee with the executives there. And I’d be monitoring it… And [I would] be there when it’s going wrong. People like to be there when it’s going right.” (Case 1—Interview–Chief of Staff)
Having key governance processes, such as discussions on ethical issues or company direction, being highly visible and inclusive helped to keep teams motivated and engaged, especially in virtual and thus potentially isolating or siloed work environments.
“It really speaks to you know being in that supportive environment where we can listen to everyone’s concerns…So the fact that we are able to bake in, you know, being considerate of a client’s time and everyone’s time but still take the due diligence in order to be able to say can we [navigate this challenge] differently and more responsibly, I’m very happy to be a part of something like that. (Case 3—Interview—Data Engineering)
Ultimately, one of the best remedies against burnout and promoters of effective team functioning was that participants on both the public and private side of the partnerships we studied found that their work during the pandemic was valuable and impactful.
“Working in healthcare as a non-clinician… you want to be able to draw that line between what you’re doing and what the patient impact is in as short a distance as possible. And I think what we’ve been able to do during the pandemic is as short a distance between those two points as you can get.” (Case 1—Interview—Sales)
Discussion
We found that key aspects of adaptive governance were adopted in three distinct partnerships between health organizations and private technology companies to deploy digital technologies as part of COVID-19 pandemic response. While the emergency context created considerable pressures with respect to time and resources, the partnerships we studied were able to use a wide range of governance structures and processes to ensure they were continuously aligned on shared goals. We found that governance processes were continuously refined and streamlined in response to logistical pressures but that certain processes, such as stakeholder engagement and monitoring for the emergence of new risks, were identified as essential. Most of the insights were drawn from key informant interviews, as publicly available documents did not frequently address the inner workings of these partnerships. Taken together, our findings suggest that effective and responsible cross-sector partnerships to deploy digital technologies during health emergencies are possible with several elements that enabled successful collaboration outlined in our findings. However, some learnings can be used to design and improve future health technology (healthtech) partnerships.
Both Blasimme and Vayena’s framework of adaptive governance through systematic oversight and Gasser et al.’s navigation aid were helpful when applied to our real-world cases [20,45–47]. Although Blasimme and Vayena’s framework was designed specifically around big data research, we found that many concepts were applicable to digital technologies more broadly. For example, Blasimme and Vayena defined “reflexivity” as an awareness of the harmful, classificatory impact of machine learning algorithms, but we found reflexivity to be applicable in broader terms such as an awareness of how deploying virtual care technology could cause harm due to the digital divide [56–58]. Our key informants were able to enact many aspects of these two frameworks into practice, even though they were not explicitly used or perhaps were not aware of them. Thus, an important area for knowledge translation could be to improve the visibility of these frameworks to key actors engaging in partnerships via integration in formal education or upskilling. Participants often spoke to best practices from their respective fields as guiding their work, such as plan-do-study-act (PDSA) cycles for clinicians and the Information Technology Infrastructure Library and The Open Group Dependability Through AssurednessTM (O-DA) Architecture Framework for informaticians [59–61].
While frameworks and best practices can be helpful while governing private sector partnerships, our findings also emphasize that firms should not necessarily chase a “silver bullet” governance arrangement. Rather these higher-level guidelines on governance structures and mechanisms should be interpreted as such. Across our cases of study, we found a high degree of “bricolage”, or improvisation, by actors in both the private and public sector to navigate their partnership [62,63]. Given the importance of experimentation, it stands to reason that partnerships that are in place prior to an emergency can leverage the “peacetime” environment to conduct the necessary experimentation to determine what works best in their own context. Experimentation around governance models has long been explored in the realm of climate governance, but is relatively new in digital health [64].
Our findings also demonstrate the importance of viewing digital technology deployments in health as complex, socio-technical systems. It would be incorrect to assume that private sector actors can “parachute in” and fix problems, especially in a crisis. As digital technologies change workflows, teamwork across a wide range of stakeholders is needed to repair these workflows and move forward to a new equilibrium [65]. The success of the partnerships in our study hinged on meaningful engagement across the entire pipeline from problem identification to solution deployment and evaluation. Health organizations should focus on their understanding, and ultimately ownership, of the core problem to ensure alignment for the partnership. Marwaha and colleagues highlight the role of key players within the health system such as clinical champions and executive sponsors as drivers of this alignment, but our work also demonstrates that it becomes important who they are connected to on their partner side and how [66]. At a broader level, human resource and capital considerations (e.g., burnout, people skills) were not captured in our guiding frameworks but should not be ignored as a key driver of effective and responsible governance [67].
The healthtech landscape in industry is largely bimodal, with major, incumbent multinationals (e.g., Google, Apple, Microsoft) on one side and startups on the other [41]. A key strength of our work was to focus on the relatively understudied role of smaller companies and startups in the context of a public health emergency. Our findings support existing literature that startups are highly agile and able to tailor their offerings to local needs, which makes them valuable contributors to crisis response [35]. However, the pandemic has created an additional layer of stress on firms that already have to navigate uncertain business conditions and reveals areas of improvement to better support these vulnerable entities. Healthtech startups must be careful to maintain their core value proposition and grow sustainably, even when an emergency context provides an impetus for new partnerships to form with hospitals and public health organizations. In many provinces in Canada, hospitals and public health organizations are public entities that are subject to public sector accountability acts. These acts outline rules for procuring technologies that are meant to promote fairness, competition, and the responsible spending of taxpayer dollars. However, many respondents felt that these guidelines make the procurement process too slow, cumbersome, and stifle the ability of non-incumbents to compete given lengthy sales cycles—even outside of an emergency context. To address these issues, the United Kingdom created a Procurement Policy Note in March 2020 that outlined criteria for public sector purchasers to issue direct awards or launch competitions with accelerated timescales [68]. Outside of emergencies, innovation accelerators embedded in health organizations can offer a testbed for governance experimentation, increase risk tolerance, and formalize social learning. The National Health Service (NHS) has developed a series of pathways to foster the invention, development, and implementation of innovations, including digital technologies [69,70]. These pathways exist to, among other functions, accelerate otherwise labyrinthine procurement processes for small and medium-sized companies, create pilot sites for deployments in partnership with academic medical centers, and support a class of fellows in scaling innovations across the country [69,70]. Similar accelerators exist at academic medical centers in the United States, such as at the University of California San Francisco and Mass General Brigham [71,72].
The interpretation of our findings should be considered in light of certain limitations. Firstly, the three cases of study in this work do not exhaustively cover every application of pandemic technology but are broadly representative of major categories (i.e., clinical, operational, and epidemiological). Secondly, the partnerships studied here can be deemed successful (i.e., they all reached the deployment phase) and maintain ongoing business relationships. Thus it is possible there is an element of social desirability as well as recall bias among our key informants leading to an overly positive appraisal of the partnership and events therein. Throughout our interviews, we attempted to address this issue and obtain critical perspectives by probing participants on what they thought could have gone differently or be improved as well as reassuring them that we would protect their anonymity (i.e., both personally and organizationally) to help them speak freely. Most interviews were conducted with managers and other participants at senior levels within the organizations of study, but we believe these perspectives are appropriate since it is leadership who generally steer the direction and priorities of partnerships. Finally, our study relied on publicly available documents—which we found were helpful for outlining that a partnership formed or key outcomes but not often why certain decisions were made and how those outcomes were achieved. This is in contrast to a popular study by Powles and Hodgson who obtained documents (e.g., contracts) on the partnership between the NHS Royal Free Trust and Deepmind through a freedom of information request [22]. We addressed this limitation in publicly available documents by conducting extensive interviews with key informants. These interviews were contingent on goodwill and building trust with our key informants by conveying that our study sought to explore how to ultimately improve the functioning of future partnerships. A freedom of information request can quickly undermine this goodwill. We caution that researchers consider the benefits and drawbacks of such an approach.
The limitation on publicly available documents also speaks to an important area of future work. When asked about transparency, our key informants stressed that publicly-directed communications about a given partnership might not be appropriate because communication should be meaningful and prioritized around key stakeholder needs. This finding creates tension with the prevailing view in the literature that transparency is essential for maintaining social license [11,73,74]. Indeed, there has been criticism of public registries of artificial intelligence algorithms in Amsterdam and Helsinki since they are not, in isolation, a sufficient governance solution to ensure ethical use [75]. Unfortunately, we were unable to provide guidance around how those communications, and to a further extent public engagement, should be operationalized. Standards, regulations, and expectations around transparency are also highly likely to be variable between jurisdictions. Future work should explore how to effectively and pragmatically foster transparency and public engagement around partnerships between health organizations and technology companies, especially in the context of a health emergency. Finally, we believe that as partnerships between digital health organizations and technology companies increase in frequency, future work should continue to take conceptual frameworks and seek to explore their relevance and impact empirically in real-world contexts.
Conclusion
Strong public-private partnerships are essential to maintain resilient health systems. Despite the considerable time and resource pressures of the COVID-19 pandemic, we found that key aspects of adaptive governance, such as social learning and flexibility around governance processes, helped foster effective and responsible partnerships between health organizations and technology companies. COVID-19 has accelerated the digital transformation of health systems globally, and a return to the pre-pandemic normal is increasingly unlikely. Stakeholders must leverage the learnings from the ongoing pandemic to navigate not only future crises but also as private technology companies continue to expand their role in health.
Supporting information
S1 File.
Appendix A–Anonymized Search Terms. Appendix B–Consent Form. Appendix C–Semi-structured Interview Guide. Appendix D–Coding Guide.
https://doi.org/10.1371/journal.pdig.0000164.s001
(PDF)
Acknowledgments
We would like to thank our study participants for sharing their insights and experiences.
References
- 1. Haldane V, De Foo C, Abdalla SM, Jung A-S, Tan M, Wu S, et al. Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries. Nat Med. 2021;27: 964–980. pmid:34002090
- 2. Kruk ME, Ling EJ, Bitton A, Cammett M, Cavanaugh K, Chopra M, et al. Building resilient health systems: a proposal for a resilience index. BMJ. 2017;357: j2323. pmid:28536191
- 3. Public Health Agency of Canada. LESSONS LEARNED REVIEW: PUBLIC HEALTH AGENCY OF CANADA AND HEALTH CANADA RESPONSE TO THE 2009 H1N1 PANDEMIC. 2010.
- 4. World Economic Forum. Managing the Risk and Impact of Future Epidemics: Options for Public-Private Cooperation. 2015.
- 5. Duff JH, Liu A, Saavedra J, Batycki JN, Morancy K, Stocking B, et al. A global public health convention for the 21st century. Lancet Public Health. 2021;6: e428–e433. pmid:33964227
- 6. Budd J, Miller BS, Manning EM, Lampos V, Zhuang M, Edelstein M, et al. Digital technologies in the public-health response to COVID-19. Nat Med. 2020;26: 1183–1192. pmid:32770165
- 7. Wymant C, Ferretti L, Tsallis D, Charalambides M, Abeler-Dörner L, Bonsall D, et al. The epidemiological impact of the NHS COVID-19 app. Nature. 2021;594: 408–412. pmid:33979832
- 8. Burgos RM, Badowski ME, Drwiega E, Ghassemi S, Griffith N, Herald F, et al. The race to a COVID-19 vaccine: opportunities and challenges in development and distribution. Drugs Context. 2021;10: 2020–2022. pmid:33643421
- 9. Wynants L, Van Calster B, Collins GS, Riley RD, Heinze G, Schuit E, et al. Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal. BMJ. 2020;369: m1328. pmid:32265220
- 10. Buckee C, Balsari S, Schroeder A. Making data for good better. PLOS Digital Health. 2022;1: e0000010.
- 11. Shaw JA, Sethi N, Cassel CK. Social license for the use of big data in the COVID-19 era. NPJ Digit Med. 2020;3: 128. pmid:33083563
- 12.
Boutilier RG, Thomson I. Social License to Operate. 3rd ed. In: Darling P, editor. SME Mining Engineering Handbook. 3rd ed. Society for Mining, Metallurgy, and Exploration; 2011. pp. 1779–1797.
- 13.
Capasso M, Umbrello S. Big Tech corporations and AI: A Social License to Operate and Multi-Stakeholder Partnerships in the Digital Age. 1st ed. In: Mazzi F, Floridi L, editors. The Ethics of Artificial Intelligence for the Sustainable Development Goals. 1st ed. Cham, Switzerland: Springer Nature Switzerland AG.; 2023.
- 14. Gunningham N, Kagan RA, Thornton D. Social License and Environmental Protection: Why Businesses Go beyond Compliance. Law & Social Inquiry. 2004;29: 307–341. Available: http://www.jstor.org/stable/4092687
- 15.
Office of the Privacy Commissioner of Canada. The Privacy Act in brief. In: The Privacy Act [Internet]. Aug 2019 [cited 26 Oct 2022]. Available: https://www.priv.gc.ca/en/privacy-topics/privacy-laws-in-canada/the-privacy-act/pa_brief/
- 16.
Office of the Privacy Commissioner of Canada. PIPEDA in brief. In: The Personal Information Protection and Electronic Documents Act (PIPEDA) [Internet]. May 2019 [cited 26 Oct 2022]. Available: https://www.priv.gc.ca/en/privacy-topics/privacy-laws-in-canada/the-personal-information-protection-and-electronic-documents-act-pipeda/pipeda_brief/
- 17.
Office of the Information and Privacy Commissioner of Ontario. Your health privacy rights in Ontario. In: Health–individuals [Internet]. 2022 [cited 26 Oct 2022]. Available: https://www.ipc.on.ca/health-individuals/file-a-health-privacy-complaint/your-health-privacy-rights-in-ontario/
- 18. Wachter RM, Cassel CK. Sharing Health Care Data With Digital Giants: Overcoming Obstacles and Reaping Benefits While Protecting Patients. JAMA. 2020;323: 507–508. pmid:31944216
- 19. Amann J, Sleigh J, Vayena E. Digital contact-tracing during the Covid-19 pandemic: An analysis of newspaper coverage in Germany, Austria, and Switzerland. PLoS One. 2021;16: e0246524. pmid:33534839
- 20. Gasser U, Ienca M, Scheibner J, Sleigh J, Vayena E. Digital tools against COVID-19: taxonomy, ethical challenges, and navigation aid. Lancet Digit Health. 2020;2: e425–e434. pmid:32835200
- 21. Whitelaw S, Mamas MA, Topol E, Van Spall HGC. Applications of digital technology in COVID-19 pandemic planning and response. Lancet Digit Health. 2020;2: e435–e440. pmid:32835201
- 22. Powles J, Hodson H. Google DeepMind and healthcare in an age of algorithms. Health Technol (Berl). 2017/03/16. 2017;7: 351–367. pmid:29308344
- 23. Harish V, Morgado F, Stern AD, Das S. Artificial Intelligence and Clinical Decision Making: The New Nature of Medical Uncertainty. Academic Medicine. 2021;96. pmid:32852320
- 24. The Medical Futurist. The First Database Of Tech Giants Collaborating With Healthcare: What Can We Learn? In: The Medical Futurist [Internet]. 13 Sep 2022 [cited 26 Oct 2022]. Available: https://medicalfuturist.com/the-first-database-of-tech-giants-collaborating-with-healthcare-what-can-we-learn/
- 25. Krasniansky A, Evans B, Zweig M. 2021 year-end digital health funding: Seismic shifts beneath the surface. In: Rock Health—Insights [Internet]. 10 Jan 2022 [cited 26 Oct 2022]. Available: https://rockhealth.com/insights/2021-year-end-digital-health-funding-seismic-shifts-beneath-the-surface/
- 26. Private Equity Wire. UK and US drive global growth in healthtech sector. In: Surveys & Research [Internet]. 19 Nov 2021 [cited 26 Oct 2022]. Available: https://www.privateequitywire.co.uk/2021/11/19/309475/uk-and-us-drive-global-growth-healthtech-sector
- 27. Reuter E. As Covid-19 cases surge, Multicare partners with startup to launch hospital-at-home program. In: MedCity News [Internet]. 11 Dec 2020 [cited 26 Oct 2022]. Available: https://medcitynews.com/2020/12/as-covid-19-cases-surge-multicare-partners-with-startup-to-launch-hospital-at-home-program/
- 28. Toub M. The art of the pivot: How Toronto startup Verto changed course to help deliver 6M vaccines. In: StartUpHere Toronto [Internet]. 25 Jan 2022 [cited 26 Oct 2022]. Available: https://startupheretoronto.com/type/startup-news/the-art-of-the-pivot-how-toronto-startup-verto-changed-course-to-help-deliver-6m-vaccines/
- 29. UKTN Staff Reporter. London AI startup Faculty partners with NHS to make better predictions for patients’ requirements. In: UK Tech News (UKTN) [Internet]. 26 Apr 2021 [cited 26 Oct 2022]. Available: https://www.uktech.news/news/london-ai-startup-faculty-partners-with-nhs-20210426
- 30. Freeman J, Carroll GR, Hannan MT. The Liability of Newness: Age Dependence in Organizational Death Rates. Am Sociol Rev. 1983;48: 692–710.
- 31. Eggers F. Masters of disasters? Challenges and opportunities for SMEs in times of crisis. J Bus Res. 2020;116: 199–208. pmid:32501306
- 32.
Stinchcombe AL. Social structure and organizations. In: Baum JAC, Dobbin F, editors. Economics Meets Sociology in Strategic Management. Emerald Group Publishing Limited; 2000. pp. 229–259. https://doi.org/10.1016/S0742-3322(00)17019-6
- 33. Baum JAC, Calabrese T, Silverman BS. Don’t go it alone: alliance network composition and startups’ performance in Canadian biotechnology. Strategic Management Journal. 2000;21: 267–294. https://doi.org/10.1002/(SICI)1097-0266(200003)21:3<267::AID-SMJ89>3.0.CO;2-8
- 34. Oukes T, von Raesfeld A, Groen A. Power in a startup’s relationships with its established partners: Interactions between structural and behavioural power. Industrial Marketing Management. 2019;80: 68–83. https://doi.org/10.1016/j.indmarman.2017.12.007
- 35. Smallbone D, Deakins D, Battisti M, Kitching J. Small business responses to a major economic downturn: Empirical perspectives from New Zealand and the United Kingdom. International Small Business Journal. 2012;30: 754–777.
- 36. Eggers F, Hansen DJ, Davis AE. Examining the relationship between customer and entrepreneurial orientation on nascent firms’ marketing strategy. International Entrepreneurship and Management Journal. 2012;8: 203–222.
- 37. Noelia F-L, Diaz-Carrion R. A dynamic analysis of the role of entrepreneurial ecosystems in reducing innovation obstacles for startups. Journal of Business Venturing Insights. 2020;14: e00192. https://doi.org/10.1016/j.jbvi.2020.e00192
- 38. Naughton J. Can big tech ever be reined in? In: The Guardian [Internet]. 21 Nov 2021 [cited 26 Oct 2022]. Available: https://www.theguardian.com/technology/2021/nov/21/can-big-tech-ever-be-reined-in
- 39. Pilkington E. Google’s secret cache of medical data includes names and full details of millions–whistleblower. In: The Guardian [Internet]. 12 Nov 2019 [cited 26 Oct 2022]. Available: https://www.theguardian.com/technology/2019/nov/12/google-medical-data-project-nightingale-secret-transfer-us-health-information
- 40. Powles J, Hodson H. Google DeepMind and healthcare in an age of algorithms. Health Technol (Berl). 2017;7: 351–367. pmid:29308344
- 41. Chakraborty I, Ilavarasan PV, Edirippulige S. Health-tech startups in healthcare service delivery: A scoping review. Soc Sci Med. 2021;278: 113949. pmid:33901972
- 42. Haines A, Kuruvilla S, Borchert M. Bridging the implementation gap between knowledge and action for health. Bull World Health Organ. 2004;82: 724–31; discussion 732. pmid:15643791
- 43.
Yin RK. Case Study Research and Applications—Design and Methods. Sixth Edit. Thousand Oaks, CA: SAGE Publications Inc; 2018.
- 44. Shaw J, Rudzicz F, Jamieson T, Goldfarb A. Artificial Intelligence and the Implementation Challenge. J Med Internet Res. 2019;21: e13659. pmid:31293245
- 45. Vayena E, Blasimme A. Health Research with Big Data: Time for Systemic Oversight. Journal of Law, Medicine & Ethics. 2021/01/01. 2018;46: 119–129. pmid:30034208
- 46.
Blasimme A, Vayena E. The Ethics of AI in Biomedical Research, Patient Care, and Public Health. In: Dubber M, Pasquale F, Das S, editors. The Oxford Handbook of Ethics of Artificial Intelligence. Oxford University Press; 2020. https://doi.org/10.1093/oxfordhb/9780190067397.013.45
- 47.
Blasimme A, Vayena E. Towards Adaptive Governance in Big Data Health Research: Implementing Regulatory Principles. Cambridge Handbook of Health Research Regulation (Forthcoming). Cambridge, United Kingdom: Cambridge University Press,; 2021. pp. 1–24.
- 48. Folke C, Hahn T, Olsson P, Norberg J. ADAPTIVE GOVERNANCE OF SOCIAL-ECOLOGICAL SYSTEMS. Annu Rev Environ Resour. 2005;30: 441–473.
- 49. Chaffin BC, Gosnell H, Cosens BA. A decade of adaptive governance scholarship: synthesis and future directions. Ecology and Society. 19.
- 50. Blasimme A, Vayena E. What’s next for COVID-19 apps? Governance and oversight. Science (1979). 2020;370: 760 LP– 762. pmid:33184192
- 51. Char DS, Abramoff MD, Feudtner C. Identifying Ethical Considerations for Machine Learning Healthcare Applications. American Journal of Bioethics. 2020. pmid:33103967
- 52. Leslie D. Understanding artificial intelligence ethics and safety. 2019.
- 53. Timmermans S, Tavory I. Theory Construction in Qualitative Research: From Grounded Theory to Abductive Analysis. Sociol Theory. 2012;30: 167–186.
- 54. Malterud K, Siersma VD, Guassora AD. Sample Size in Qualitative Interview Studies: Guided by Information Power. Qual Health Res. 2016;26: 1753–1760. pmid:26613970
- 55.
Bandura A, Walters RH. Social learning and personality. New York, NY, USA: Holt, Rinehart & Winston; 1963.
- 56. Sieck CJ, Sheon A, Ancker JS, Castek J, Callahan B, Siefer A. Digital inclusion as a social determinant of health. NPJ Digit Med. 2021;4: 52. pmid:33731887
- 57. Eberly LA, Kallan MJ, Julien HM, Haynes N, Khatana SAM, Nathan AS, et al. Patient Characteristics Associated With Telemedicine Access for Primary and Specialty Ambulatory Care During the COVID-19 Pandemic. JAMA Netw Open. 2020;3: e2031640–e2031640. pmid:33372974
- 58. Chunara R, Zhao Y, Chen J, Lawrence K, Testa PA, Nov O, et al. Telemedicine and healthcare disparities: a cohort study in a large healthcare system in New York City during COVID-19. Journal of the American Medical Informatics Association. 2021;28: 33–41. pmid:32866264
- 59. Verma AA, Murray J, Greiner R, Cohen JP, Shojania KG, Ghassemi M, et al. Implementing machine learning in medicine. Can Med Assoc J. 2021;193: E1351 LP–E1357. pmid:35213323
- 60. Nyhuis M. What is the ITIL Framework? In: Diligent. 2020.
- 61. The Open Group. Dependability through AssurednessTM (O-DA) Framework. 2022.
- 62. Nelson R, Lima E. Effectuations, social bricolage and causation in the response to a natural disaster. Small Business Economics. 2020;54: 721–750.
- 63. Kuckertz A, Brändle L, Gaudig A, Hinderer S, Morales Reyes CA, Prochotta A, et al. Startups in times of crisis–A rapid response to the COVID-19 pandemic. Journal of Business Venturing Insights. 2020;13: e00169.
- 64. Chu EK. The Governance of Climate Change Adaptation Through Urban Policy Experiments. Environmental Policy and Governance. 2016;26: 439–451. https://doi.org/10.1002/eet.1727
- 65. Elish MC, Watkins EA. Repairing Innovation: A Study of Integrating AI in Clinical Care. New York, NY, USA; 2020.
- 66. Marwaha JS, Landman AB, Brat GA, Dunn T, Gordon WJ. Deploying digital health tools within large, complex health systems: key considerations for adoption and implementation. NPJ Digit Med. 2022;5: 13. pmid:35087160
- 67. Giones F, Brem A, Pollack JM, Michaelis TL, Klyver K, Brinckmann J. Revising entrepreneurial action in response to exogenous shocks: Considering the COVID-19 pandemic. Journal of Business Venturing Insights. 2020;14: e00186. https://doi.org/10.1016/j.jbvi.2020.e00186
- 68.
The United Kingdom Cabinet Office. Procurement Policy Note—Responding to COVID-19 Information Note PPN 01/20 March 2020. London, UK; 2020.
- 69. Arora A, Wright A, Cheng M, Khwaja Z, Seah M. Innovation Pathways in the NHS: An Introductory Review. Ther Innov Regul Sci. 2021;55: 1045–1058. pmid:34009551
- 70. Kelly CJ, Young AJ. Promoting innovation in healthcare. Future Healthc J. 2017;4: 121–125. pmid:31098448
- 71. DePasse JW, Chen CE, Sawyer A, Jethwani K, Sim I. Academic Medical Centers as digital health catalysts. Healthcare. 2014;2: 173–176. pmid:26250503
- 72.
Mass General Brigham. Innovation Fellows Program. In: Mass General Brigham Innovation [Internet]. 2022 [cited 25 Apr 2022]. Available: https://innovation.massgeneralbrigham.org/about/special-programs/innovation-fellows-program
- 73. Floridi L. Artificial Intelligence as a Public Service: Learning from Amsterdam and Helsinki. Philos Technol. 2020;33: 541–546.
- 74. Policies EO on HS and, Tille F, Panteli D, Fahy N, Waitzberg R, Davidovitch N, et al. Governing the public-private-partnerships of the future: learnings from the experiences in pandemic times. Eurohealth (Lond). 2021;27: 49–53.
- 75. Cath C, Jansen F. Dutch Comfort: The limits of AI governance through municipal registers. arXiv preprint arXiv:210902944. 2021.